STOA Study on “Improving access to medicines and promoting pharmaceutical innovation”
In the context of the negotiations of the pharmaceutical package, the authors of the STOA Study on “Improving access to medicines and promoting pharmaceutical innovation” held a presentation before ENVI on 4 December.
The study seeks to address the challenges faced by the current system of pharmaceutical innovation , such as the partial misalignment between industry research and development priorities and public health goals, and market access constraints.
According to one of it's main findings, exclusivities have an important role in fostering R&D activities by the private sector. Nevertheless, unless explicitly targeted, their ability to address unmet medical needs is limited.
To tackle the identified issues, the study proposes policy options that seek to ensure the development of accessible drugs in all clinical areas, improve availability, price and research and development cost transparency, and ensure preparedness in the event of emergencies.